The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer

Christopher J. Sweeney, Sanjana Mehrotra, Miral R. Sadaria, Suresh Kumar, Nicholas H. Shortle, Yaritzabel Roman, Carol Sheridan, Robert A. Campbell, Daryl J. Murry, Sunil Badve, Harikrishna Nakshatri

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor κB (NF-κB) and activation of the c-Jun NH2-terminal kinase. In this study, we investigated the chemosensitizing activity of parthenolide in vitro as well as in MDA-MB-231 cell-derived xenograft metastasis model of breast cancer. HBL-100 and MDA-MB-231 cells were used to measure the antitumor and chemosensitizing activity of parthenolide in vitro. Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45β1 in vitro. In an adjuvant setting, animals treated with parthenolide and docetaxel combination showed significantly enhanced survival compared with untreated animals or animals treated with either drug. The enhanced survival in the combination arm was associated with reduced lung metastases. In addition, nuclear NF-κB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. In the established orthotopic model, there was a trend toward slower growth in the parthenolide-treated animals but no statistically significant findings were seen. These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-κB.

Original languageEnglish (US)
Pages (from-to)1004-1012
Number of pages9
JournalMolecular cancer therapeutics
Volume4
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

docetaxel
Sesquiterpenes
Lactones
Heterografts
Breast Neoplasms
Neoplasm Metastasis
Lung
parthenolide
JNK Mitogen-Activated Protein Kinases
Residual Neoplasm
Interleukin-8

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. / Sweeney, Christopher J.; Mehrotra, Sanjana; Sadaria, Miral R.; Kumar, Suresh; Shortle, Nicholas H.; Roman, Yaritzabel; Sheridan, Carol; Campbell, Robert A.; Murry, Daryl J.; Badve, Sunil; Nakshatri, Harikrishna.

In: Molecular cancer therapeutics, Vol. 4, No. 6, 01.06.2005, p. 1004-1012.

Research output: Contribution to journalArticle

Sweeney, Christopher J. ; Mehrotra, Sanjana ; Sadaria, Miral R. ; Kumar, Suresh ; Shortle, Nicholas H. ; Roman, Yaritzabel ; Sheridan, Carol ; Campbell, Robert A. ; Murry, Daryl J. ; Badve, Sunil ; Nakshatri, Harikrishna. / The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. In: Molecular cancer therapeutics. 2005 ; Vol. 4, No. 6. pp. 1004-1012.
@article{750e08de6c034fcb951d1d309ca8d362,
title = "The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer",
abstract = "Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor κB (NF-κB) and activation of the c-Jun NH2-terminal kinase. In this study, we investigated the chemosensitizing activity of parthenolide in vitro as well as in MDA-MB-231 cell-derived xenograft metastasis model of breast cancer. HBL-100 and MDA-MB-231 cells were used to measure the antitumor and chemosensitizing activity of parthenolide in vitro. Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45β1 in vitro. In an adjuvant setting, animals treated with parthenolide and docetaxel combination showed significantly enhanced survival compared with untreated animals or animals treated with either drug. The enhanced survival in the combination arm was associated with reduced lung metastases. In addition, nuclear NF-κB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. In the established orthotopic model, there was a trend toward slower growth in the parthenolide-treated animals but no statistically significant findings were seen. These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-κB.",
author = "Sweeney, {Christopher J.} and Sanjana Mehrotra and Sadaria, {Miral R.} and Suresh Kumar and Shortle, {Nicholas H.} and Yaritzabel Roman and Carol Sheridan and Campbell, {Robert A.} and Murry, {Daryl J.} and Sunil Badve and Harikrishna Nakshatri",
year = "2005",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-05-0030",
language = "English (US)",
volume = "4",
pages = "1004--1012",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer

AU - Sweeney, Christopher J.

AU - Mehrotra, Sanjana

AU - Sadaria, Miral R.

AU - Kumar, Suresh

AU - Shortle, Nicholas H.

AU - Roman, Yaritzabel

AU - Sheridan, Carol

AU - Campbell, Robert A.

AU - Murry, Daryl J.

AU - Badve, Sunil

AU - Nakshatri, Harikrishna

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor κB (NF-κB) and activation of the c-Jun NH2-terminal kinase. In this study, we investigated the chemosensitizing activity of parthenolide in vitro as well as in MDA-MB-231 cell-derived xenograft metastasis model of breast cancer. HBL-100 and MDA-MB-231 cells were used to measure the antitumor and chemosensitizing activity of parthenolide in vitro. Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45β1 in vitro. In an adjuvant setting, animals treated with parthenolide and docetaxel combination showed significantly enhanced survival compared with untreated animals or animals treated with either drug. The enhanced survival in the combination arm was associated with reduced lung metastases. In addition, nuclear NF-κB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. In the established orthotopic model, there was a trend toward slower growth in the parthenolide-treated animals but no statistically significant findings were seen. These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-κB.

AB - Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor κB (NF-κB) and activation of the c-Jun NH2-terminal kinase. In this study, we investigated the chemosensitizing activity of parthenolide in vitro as well as in MDA-MB-231 cell-derived xenograft metastasis model of breast cancer. HBL-100 and MDA-MB-231 cells were used to measure the antitumor and chemosensitizing activity of parthenolide in vitro. Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45β1 in vitro. In an adjuvant setting, animals treated with parthenolide and docetaxel combination showed significantly enhanced survival compared with untreated animals or animals treated with either drug. The enhanced survival in the combination arm was associated with reduced lung metastases. In addition, nuclear NF-κB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. In the established orthotopic model, there was a trend toward slower growth in the parthenolide-treated animals but no statistically significant findings were seen. These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-κB.

UR - http://www.scopus.com/inward/record.url?scp=21344454493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344454493&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0030

DO - 10.1158/1535-7163.MCT-05-0030

M3 - Article

C2 - 15956258

AN - SCOPUS:21344454493

VL - 4

SP - 1004

EP - 1012

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -